- Previous Close
0.0303 - Open
0.0303 - Bid 0.0450 x --
- Ask 0.0550 x --
- Day's Range
0.0303 - 0.0303 - 52 Week Range
0.0240 - 0.0770 - Volume
100 - Avg. Volume
1,449 - Market Cap (intraday)
6.31M - Beta (5Y Monthly) 1.68
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 27, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was incorporated in 1984 and is headquartered in Houston, Texas.
propcitweb.ddns.net:83Recent News: BZYR
View MorePerformance Overview: BZYR
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BZYR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BZYR
View MoreValuation Measures
Market Cap
6.34M
Enterprise Value
6.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-105,469.07%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.46M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
613
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
66.75k